+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Multiple Sclerosis Market Research Report by Treatment Modality (Injectable Agents and Oral Agents), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • PDF Icon

    Report

  • 259 Pages
  • July 2022
  • Region: Global
  • 360iResearch™
  • ID: 4968783
UP TO OFF until Dec 31st 2022
The Global Multiple Sclerosis Market size was estimated at USD 14.30 billion in 2021, USD 15.44 billion in 2022, and is projected to grow at a CAGR 8.15% to reach USD 22.89 billion by 2027.

Market Statistics:


The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Multiple Sclerosis to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Treatment Modality, the market was studied across Injectable Agents and Oral Agents.
  • Based on Application, the market was studied across Hospital and Research.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Multiple Sclerosis market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Multiple Sclerosis Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Multiple Sclerosis Market, including AbbVie Inc., Bayer HealthCare Pharmaceuticals LLC, Biogen Idec, F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi Aventis, Synthetic Biologics, Inc., and Teva Pharmaceuticals Industries Ltd..

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Multiple Sclerosis Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Multiple Sclerosis Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Multiple Sclerosis Market?
4. What is the competitive strategic window for opportunities in the Global Multiple Sclerosis Market?
5. What are the technology trends and regulatory frameworks in the Global Multiple Sclerosis Market?
6. What is the market share of the leading vendors in the Global Multiple Sclerosis Market?
7. What modes and strategic moves are considered suitable for entering the Global Multiple Sclerosis Market?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Robust investment in research and development activities globally
5.1.1.2. Favorable government support to increase the awareness among people
5.1.1.3. Rising incidence of MS in young and elderly people
5.1.2. Restraints
5.1.2.1. Relatively high cost of the drugs
5.1.3. Opportunities
5.1.3.1. Increasing preference for oral drugs such as Copaxone and Tysabri
5.1.3.2. Emerging novel pipeline of drugs by key market players
5.1.4. Challenges
5.1.4.1. Stringent regulatory policies for drug approval
5.2. Cumulative Impact of COVID-19
6. Multiple Sclerosis Market, by Treatment Modality
6.1. Introduction
6.2. Injectable Agents
6.3. Oral Agents
7. Multiple Sclerosis Market, by Application
7.1. Introduction
7.2. Hospital
7.3. Research
8. Americas Multiple Sclerosis Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Multiple Sclerosis Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Multiple Sclerosis Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. AbbVie Inc.
12.2. Bayer HealthCare Pharmaceuticals LLC
12.3. Biogen Idec
12.4. F. Hoffmann-La Roche AG
12.5. Merck & Co. Inc.
12.6. Novartis International AG
12.7. Pfizer Inc.
12.8. Sanofi Aventis
12.9. Synthetic Biologics, Inc.
12.10. Teva Pharmaceuticals Industries Ltd.
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL MULTIPLE SCLEROSIS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2021 VS 2027 (USD BILLION)
FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2021 VS 2027 (%)
FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 6. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2027
FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET DYNAMICS
FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2021 VS 2027 (%)
FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2021 VS 2027 (USD BILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2027
FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, 2019-2027 (USD BILLION)
FIGURE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (%)
FIGURE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2021 VS 2027 (USD BILLION)
FIGURE 17. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2027
FIGURE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 23. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 24. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 25. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2027
FIGURE 26. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 27. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 28. CANADA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 29. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 30. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 31. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2021 VS 2027 (%)
FIGURE 32. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2021 VS 2027 (USD BILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2027
FIGURE 34. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 36. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2027
FIGURE 38. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. INDIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (%)
FIGURE 51. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2021 VS 2027 (USD BILLION)
FIGURE 52. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2027
FIGURE 53. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 54. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 55. ITALY MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 56. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 57. QATAR MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 58. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 59. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 60. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 61. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 62. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 63. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 64. GLOBAL MULTIPLE SCLEROSIS MARKET: FPNV POSITIONING MATRIX, 2021
FIGURE 65. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2021
FIGURE 66. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL MULTIPLE SCLEROSIS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY REGION, 2019-2027 (USD BILLION)
TABLE 7. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY STATE, 2019-2027 (USD BILLION)
TABLE 9. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 10. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2019-2027 (USD BILLION)
TABLE 12. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY STATE, 2019-2027 (USD BILLION)
TABLE 14. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 15. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2019-2027 (USD BILLION)
TABLE 18. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY STATE, 2019-2027 (USD BILLION)
TABLE 20. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY REGION, 2019-2027 (USD BILLION)
TABLE 23. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY STATE, 2019-2027 (USD BILLION)
TABLE 25. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 26. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 28. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 30. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 31. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 32. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 33. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 34. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 35. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 36. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 37. CANADA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 38. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 39. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 40. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 41. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 42. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 43. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 44. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2019-2027 (USD BILLION)
TABLE 45. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 46. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 47. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 48. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 49. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 50. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 51. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 52. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 53. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 54. CHINA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 55. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 56. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 57. INDIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 58. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 59. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 60. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 61. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 62. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 63. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 65. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 66. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 68. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 69. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 71. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 72. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 73. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 74. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 75. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 76. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 77. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 78. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 79. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 80. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 81. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 82. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 83. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 88. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 89. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 90. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 91. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 92. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 93. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 94. ITALY MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 95. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 96. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 97. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 98. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 99. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 100. QATAR MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 101. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 102. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 103. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 104. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 105. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 106. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 107. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 108. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 109. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 110. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 111. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 112. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 113. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 114. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 115. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 116. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 117. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 118. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 119. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2019-2027 (USD BILLION)
TABLE 120. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2019-2027 (USD BILLION)
TABLE 121. GLOBAL MULTIPLE SCLEROSIS MARKET: FPNV POSITIONING MATRIX - SCORES, 2021
TABLE 122. GLOBAL MULTIPLE SCLEROSIS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2021
TABLE 123. GLOBAL MULTIPLE SCLEROSIS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2021
TABLE 124. GLOBAL MULTIPLE SCLEROSIS MARKET RANKING
TABLE 125. GLOBAL MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2021
TABLE 126. GLOBAL MULTIPLE SCLEROSIS MARKET MERGER & ACQUISITION
TABLE 127. GLOBAL MULTIPLE SCLEROSIS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 128. GLOBAL MULTIPLE SCLEROSIS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 129. GLOBAL MULTIPLE SCLEROSIS MARKET INVESTMENT & FUNDING
TABLE 130. GLOBAL MULTIPLE SCLEROSIS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 131. GLOBAL MULTIPLE SCLEROSIS MARKET: LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Bayer HealthCare Pharmaceuticals LLC
  • Biogen Idec
  • F. Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi Aventis
  • Synthetic Biologics, Inc.
  • Teva Pharmaceuticals Industries Ltd.

Methodology

Loading
LOADING...